Fresenius Kabi Fosaprepitant Recall: Excipient Labeling Error Impacts US Supply Chain
Fresenius Kabi USA, LLC initiated a Class III recall for 63,067 vials of Fosaprepitant for Injection due to an excipient labeling error. The carton incorrectly stated edetate disodium quantity, highlighting critical regulatory compliance and supply chain oversight needs. This event underscores the imperative for robust quality control and accurate product information for pharmaceutical procurement and regulatory teams.
FDA Identifies Critical Excipient Labeling Discrepancy in Fresenius Kabi's Fosaprepitant
Fresenius Kabi USA, LLC, operating from Lake Zurich, Illinois, initiated a voluntary, firm-initiated Class III recall (D-1391-2020) for its Fosaprepitant for Injection, 150 mg / vial. This critical action, initiated on July 13, 2020, stemmed from a significant labeling error identified on both the product's carton label and the accompanying product insert. The documentation incorrectly stated the quantity of the excipient, edetate disodium (EDTA), as 5.4 mg / vial, when the actual amount present was 18.8 mg / vial. This represents a discrepancy where the actual excipient quantity was over three times the declared amount. For procurement directors and regulatory affairs heads, this event underscores the absolute necessity of rigorous verification processes for all product documentation against manufacturing specifications. The recall encompassed 63,067 vials, distributed nationwide within the United States, across multiple specific lots including 6122760, 6122761 (exp 08/2021), 6122762 (exp 09/2021), and 6123883 (exp 03/2022). Such a substantial discrepancy, even for an excipient, can trigger extensive regulatory action, necessitate costly recall logistics, and significantly erode market trust, demanding immediate and thorough remediation efforts from manufacturers and vigilant oversight from their partners.
Commercial and Patient Safety Implications of Mislabeled Edetate Disodium (EDTA)
While the FDA classified this as a Class III recall, indicating that the product is unlikely to cause adverse health consequences, the misstatement of edetate disodium (EDTA) quantity by over 300% represents a serious breach of Good Manufacturing Practices (GMP) and fundamental labeling accuracy. EDTA is a chelating agent, and while generally safe at appropriate levels, higher concentrations can impact physiological processes, particularly calcium levels. This could pose potential, albeit low-probability, risks for sensitive patient populations, such as those with renal impairment, pediatric patients, or individuals concurrently receiving medications that interact with chelating agents. For procurement directors, this incident highlights that supplier qualification and ongoing audit processes must extend beyond active pharmaceutical ingredients (APIs) to include critical excipients and packaging components. A failure in this area, even for a Class III issue, can lead to significant supply chain disruptions, product withdrawals, and reputational damage. Regulatory affairs heads must ensure robust internal controls for label generation, meticulous review, and approval, alongside comprehensive change control processes for all components, whether active or inactive. This proactive approach is essential to mitigate the risk of similar, or more severe, compliance issues that could impact patient safety and market access.
Navigating Regulatory Scrutiny and Enhancing Supply Chain Resilience
The recall, initiated on July 13, 2020, was officially terminated on August 19, 2022. This termination signifies that Fresenius Kabi USA, LLC successfully implemented corrective actions to address the identified labeling error and satisfied the FDA's requirements, demonstrating their resolution of the immediate compliance issue. However, this event serves as a critical reminder for the broader chemical and life sciences industry regarding the continuous need for stringent quality control and unwavering labeling accuracy in pharmaceutical manufacturing. This incident, when viewed alongside other recent regulatory actions such as Real Clean Distribuciones SA de CV's methanol contamination or AVKARE Inc.'s impurity failures, underscores a pervasive need for heightened vigilance across the pharmaceutical supply chain. While the specifics of each event differ, the common thread is regulatory non-compliance, emphasizing the importance of robust quality agreements, comprehensive supplier audits, and diligent internal regulatory checks. Supply chain VPs should interpret this as a reinforcement for diversified sourcing strategies and stringent supplier qualification programs that encompass all components. Business development executives must prioritize assessing potential partners' regulatory compliance track records, as such issues can directly impact market access and product launch timelines. Proactive risk management and continuous monitoring of regulatory intelligence are indispensable for maintaining operational continuity and market integrity.